FASTPASS supports research teams developing through-packaging sensing and analytics to rapidly verify pharmaceutical quality and safety, protecting Americans from substandard or contaminated medicines.
FASTPASS now accepts submissions only from applicants who met previous deadline requirements. The posted solicitation requires a Solution Summary slide deck by September 21, 2026, at 4:00 PM ET to proceed; full proposals are due November 10, 2026, at 4:00 PM ET, and other application details also changed.
Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) supports teams developing adaptive drug and biologic trials to evaluate treatments faster, at lower cost, and with fewer participants.
NIH Challenges seeks rapid, low-cost, one-step drug testing devices able to definitively detect and quantify multiple drugs, including fentanyl, from diverse samples in under 15 minutes.
FDA grant supports collaborative projects to advance drug development, manufacturing, and regulatory science, focusing on safety, efficacy, and innovation.
QuSAFE from NIH Challenges funds quantum-enabled sensing innovations to improve predictive performance of in vitro preclinical NAMs for toxicity and safety testing.
Accelerating Drug Discovery for FTD supports investigators developing small molecule and biologic drugs through lead optimization and animal-model testing to advance disease-modifying treatments for FTD.